Blog

ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)

Photo taken from dailyreporter.esmo.org

Oct 24, 2023, 14:57

ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)

“Positive outcomes in advanced or metastatic urothelial carcinoma reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate immunotherapy and Antibody Drug Conjugates (ADCs) as an alternative to first-line chemotherapy for the first time.

Results presented at today’s Presidential Symposium at ESMO23 show that enfortumab, vedotin plus pembrolizumab and adding nivolumab to chemotherapy prolonged median Progression-free survival (PFS) and median overall survival (OS) compared with chemotherapy.

Andrea Apolo, Bethesda, USA, comments on these findings on the ESMO Daily Reporter.
Read the full article here.”

Source:

Andrea Apolo Antibody Drug Conjugates (ADCs) Bethesda cancer ESMO Daily Reporter ESMO23 European Society for Medical Oncology (ESMO) immunotherapy OncoDaily Oncology

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology